Crossmark

Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling

Crossref DOI link: https://doi.org/10.1038/s41598-022-12930-x

Published Online: 2022-05-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Devarakonda, Teja

Valle Raleigh, Juan

Mauro, Adolfo G.

Lambert, Johana M.

Cowart, Lauren Ashley

Salloum, Fadi N.
Funding

Funding for this research was provided by:

American Heart Association (18PRE33990001)

National Heart, Lung, and Blood Institute (R01HL117233, R01HL142281)

U.S. Department of Veterans Affairs (IBX0002000)

National Institute on Aging (R21AG053654)
License Information

Text and Data Mining valid from 2022-05-25

Version of Record valid from 2022-05-25
More Information

Article History

Received: 1 February 2022

Accepted: 18 May 2022

First Online: 25 May 2022

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below